Search
for
Did you mean Janus Kinase Inhibitors?
Sort by
Research 30 of 1000+
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Biologics in the management of childhood atopic dermatitis
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
- Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series